<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty-four type 2 diabetic patients with neuroischemic foot <z:mpath ids='MPATH_579'>ulcers</z:mpath> were randomised to treatment with 5000 IU of dalteparin, (n = 28), or physiological saline, (n = 26), once daily until <z:mpath ids='MPATH_579'>ulcer</z:mpath> healing or for a maximum of 6 months </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-three patients had normo-, 15 micro-, and 6 macroalbuminuria </plain></SENT>
<SENT sid="2" pm="."><plain>The urinary levels of IgM and IgG(2) were elevated in 47 and 50 patients, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Elevated urinary levels of IgM and IgG(2) indicate decreased glomerular size selectivity </plain></SENT>
<SENT sid="4" pm="."><plain>Urine IgM levels were associated with IGF-1/IGFBP-1 and IGFBP-1 levels </plain></SENT>
<SENT sid="5" pm="."><plain>Dalteparin treatment increased urinary levels of <z:chebi fb="0" ids="18085">glycosaminoglycans</z:chebi> (P &lt; 0.001) and serum IGFBP-1 (P &lt; 0.05) while no significant effects were seen in any of the other studied parameters </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, dalteparin therapy in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> had no effects on urinary levels of albumin, IgM, or IgG(2) despite significantly increased <z:chebi fb="0" ids="18085">glycosaminoglycans</z:chebi> in urine </plain></SENT>
<SENT sid="7" pm="."><plain>Elevated urinary levels of IgM and IgG(2) might be more sensitive markers of <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> than <z:mp ids='MP_0002871'>albuminuria</z:mp> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy </plain></SENT>
</text></document>